Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
41.36
+1.79 (4.52%)
At close: Jul 30, 2026, 4:00 PM EDT
41.48
+0.12 (0.29%)
After-hours: Jul 30, 2026, 7:51 PM EDT
Cogent Biosciences Employees
Cogent Biosciences had 258 employees as of December 31, 2025. The number of employees increased by 53 or 25.85% compared to the previous year.
Employees
258
Change (1Y)
53
Growth (1Y)
25.85%
Revenue / Employee
n/a
Profits / Employee
-$1,373,267
Market Cap
7.07B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 258 | 53 | 25.85% |
| Dec 31, 2024 | 205 | 41 | 25.00% |
| Dec 31, 2023 | 164 | 26 | 18.84% |
| Dec 31, 2022 | 138 | 61 | 79.22% |
| Sep 30, 2022 | 121 | 44 | 57.14% |
| Dec 31, 2021 | 77 | 62 | 413.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Mirum Pharmaceuticals | 418 |
| Rhythm Pharmaceuticals | 414 |
| TG Therapeutics | 399 |
| Xenon Pharmaceuticals | 370 |
| CG Oncology | 142 |
COGT News
- 4 weeks ago - Cogent Biosciences submits bezuclastinib NDA to FDA - TheFly
- 4 weeks ago - Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) - GlobeNewsWire
- 6 weeks ago - Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress - GlobeNewsWire
- 6 weeks ago - Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress - GlobeNewsWire
- 7 weeks ago - Cogent Biosciences Transcript: AGM 2026 - Transcripts
- 2 months ago - Cogent Biosciences Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Cogent Biosciences announces data from analysis of PEAK Phase 3 trial - TheFly
- 2 months ago - Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire